Sanofi (NASDAQ:SNY) Position Lessened by Bank of Montreal Can

Bank of Montreal Can reduced its stake in shares of Sanofi (NASDAQ:SNY) by 0.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 233,086 shares of the company’s stock after selling 1,944 shares during the quarter. Bank of Montreal Can’s holdings in Sanofi were worth $11,713,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Barrow Hanley Mewhinney & Strauss LLC increased its position in Sanofi by 113.8% in the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares during the period. Magnetar Financial LLC raised its stake in shares of Sanofi by 1,153.1% during the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after purchasing an additional 2,306,286 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares during the period. Mondrian Investment Partners LTD grew its position in Sanofi by 43.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after buying an additional 1,190,141 shares in the last quarter. Finally, Armistice Capital LLC acquired a new position in Sanofi during the 4th quarter valued at about $51,520,000. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of SNY opened at $57.65 on Monday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $146.01 billion, a PE ratio of 28.97, a PEG ratio of 1.62 and a beta of 0.60. The firm’s 50 day moving average price is $55.04 and its 200 day moving average price is $50.84. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The business had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. During the same quarter in the prior year, the firm posted $0.95 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, research analysts expect that Sanofi will post 4.26 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on SNY. StockNews.com raised Sanofi from a “buy” rating to a “strong-buy” rating in a report on Thursday. Argus boosted their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.